Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 2)
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
WEDNESDAY, March 12, 2025 – Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in...
AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications
TUESDAY, March 11, 2025 – Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...
No Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration Pneumonia
THURSDAY, March 6, 2025 – Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published...
GLP-1 Drugs Improve Outlook For Kidney Transplants
THURSDAY, March 6, 2025 – GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients’ type 2 diabetes and p...
Obesity On The Rise Worldwide, Report Says
TUESDAY, March 4, 2025 – More than half of adults and a third of children and teens worldwide will be overweight or obese by 2050, a comprehensive global analysis has concluded. Overweight and...
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 – Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or...
Semaglutide May Reduce Craving in Alcohol Use Disorder
FRIDAY, Feb. 28, 2025 – Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry....
No Suicide Risk Associated With GLP-1 Drugs
FRIDAY, Feb. 28, 2025 – GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has concluded. Earlier research had potentially linked these drugs ...
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
MONDAY, Feb. 24, 2025 – For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared...
Ozempic, Wegovy Linked To Potential Vision Loss
MONDAY, Feb. 24, 2025 – People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition that affects the optic nerve, a new study says....
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 – For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1...
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
WEDNESDAY, Feb. 12, 2025 – Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable...
More Evidence Ozempic Can Curb Alcoholism
WEDNESDAY, Feb. 12, 2025 – Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake. The research found that, compared to...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2